Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011

Anti-Cancer Drugs

Volumn 13, Issue 1, 2002, Pages 29-36

  Boyer, Christopher R ^a   Karjian, Patricia L ^a   Wahl, Geoffrey M ^a   Pegram, Mark ^a   Neuteboom, Saskia T C ^a  

^a NewBiotics Inc   (United States)

Author keywords

Dipyridamole; NB1011; Nucleoside transport inhibitors; p nitrobenzylthioinosine

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; CISPLATIN; DIPYRIDAMOLE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; NB 1011; NITROBENZYLTHIOINOSINE; NUCLEOSIDE TRANSPORT INHIBITOR; OXALIPLATIN; PACLITAXEL; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BROMODEOXYURIDINE; CARRIER PROTEINS; CELL SURVIVAL; COLONIC NEOPLASMS; DIPYRIDAMOLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUOROURACIL; HUMANS; MEMBRANE PROTEINS; NUCLEOSIDE TRANSPORT PROTEINS; QUINAZOLINES; THIOINOSINE; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0036178440     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200201000-00003     Document Type: Article

References (37)

1. The catalytic mechanism and structure of thymidylate synthase
2. Genetic instability as a consequence of inappropriate entry into and progression through S-phase
3. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
4. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein
5. Colorectal carcinoma: Current problems and future perspectives
6. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
7. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy
8. Comparative genomic hybridization analysis of chromosomal alterations induced by the development of resistance to thymidylate synthase inhibitors
9. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
10. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
11. Drug resistance in colon cancer
12. Enzyme catalyzed therapeutic agent design: The antitumor ECTA compound NB1011 is activated by thymidylate synthase
13. A novel approach to thymidylate synthase as a target for cancer chemotherapy
14. Biochemical modulation of fluorouracil by dipyridamole: Preclinical and clinical experience
15. Resistance to tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines
16. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
17. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor
18. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
19. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
20. Mechanism of synergy between N-phosphonacetyl-1-aspartate and dipyridamole in a human ovarian carcinoma cell line
21. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines
22. Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: Implications for chemotherapy
23. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole
24. Nucleoside transport in normal and neoplastic cells
25. Enhancement of retention and cytotoxicity of 2-chlorodeoxy-adenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport
26. Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell lines
27. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole
28. Circumvention of adriamycin resistance by dipyridamole analogues: A structure-activity relationship study
29. Potentiation of methotrexate toxicity by dipyridamole
30. Phase II trial of oral methotrexate and dipyridamole in colorectal carcinoma
31. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage
32. Dipyridamole kinetics
33. Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole
34. Phase I and pharmacokinetic trial of intraperitoneal etoposide in combination with the multidrug-resistance-modulating agent dipyridamole
35. Dipyridamole binding to proteins in human plasma and tissue culture media
36. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding